Clinical Trial Update: KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD [Phase 3]

View source ↗

Summary

Open-label safety study in children aged 6-12 with ADHD completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• KP415 (unknown)

Snippet

Sponsor: Zevra Therapeutics | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2021-07-19